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Abstract: The current classification of heart failure (HF) based on left ventricular (LV) ejection fraction 
(EF) identifies a large group of patients with preserved ejection fraction (HFpEF) with significant morbidity 
and mortality but without prognostic benefit from current HF therapy. Co-morbidities and conditions 
such as arterial hypertension, diabetes mellitus, chronic kidney disease, adiposity and aging shape the 
clinical phenotype and contribute to mortality. LV diastolic dysfunction and LV structural remodeling 
are hallmarks of HFpEF, and are linked to remodeling of the cardiomyocyte and extracellular matrix. 
Pulmonary hypertension (PH) and right ventricular dysfunction (RVD) are particularly common in HFpEF, 
and mortality is up to 10-fold higher in HFpEF patients with vs. without RV dysfunction. Here, we review 
alterations in cardiomyocyte function (i.e., ion homeostasis, sarcomere function and cellular metabolism) 
associated with diastolic dysfunction and summarize the main underlying cellular pathways. The contribution 
and interaction of systemic and regional upstream signaling such as chronic inflammation, neurohumoral 
activation, and NO-cGMP-related pathways are outlined in detail, and their diagnostic and therapeutic 
potential is discussed in the context of preclinical and clinical studies. In addition, we summarize prevalence 
and pathomechanisms of RV dysfunction in the context of HFpEF and discuss mechanisms connecting LV 
and RV dysfunction in HFpEF. Dissecting the molecular mechanisms of LV and RV dysfunction in HFpEF 
may provide a basis for an improved classification of HFpEF and for therapeutic approaches tailored to the 
molecular phenotype.
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Heart failure with preserved ejection fraction 
(HFpEF)—clinical and cellular characteristics
Introduction
A 71 years old mildly overweight woman is transferred 
to the hospital with worsening dyspnea on exertion, 
unproductive cough and mild ankle edema for a few weeks. 
Once the diagnosis of heart failure (HF) is established, she 
faces a 1 in 6 chance to die within 2 years despite optimal 
current therapy (1). HF is the leading cause for hospital 
admissions, and more than 26 million people worldwide are 
affected (2). HF is diagnosed in a large variety of patients 
with different medical backgrounds. Currently, diagnosis 
is based on clinical signs and symptoms, and imaging (e.g., 
echocardiography). HF patients are classified based on 
left ventricular (LV) ejection fraction (EF) as patients with 
preserved (HFpEF, LV EF ≥50%), reduced (HFrEF, LV EF 
<40%) or mid-range EF as basis for clinical management. 
Inhibition of neurohumoral activation with ACE-
inhibitors, angiotensin-receptor blockers or betablockers, 
and enhancing the availability of natriuretic peptides (NP) 
with neprilysin inhibitors (sacubitril, in combination with 
valsartan) are effective treatments in HFrEF but failed to 
improve prognosis in HFpEF (3-5) (see also “neurohumoral 
activation” section for discussion). It is commonly argued 
that HFpEF represents a more heterogeneous disease as 
suggested by (I) the variety of clinical disease conditions 
associated with HFpEF (6), (II) very different long-term 
prognosis if HFpEF patients are classified based on the 
severity of their predominant clinical features (7), and (III) 
identification of subgroups of HFpEF patients that respond 
to medical HF therapy in pooled analyses from randomized 
controlled trials (RCTs) and observational trials (5,8). Some 
but not all studies suggest an increased number of co-
morbidities in HFpEF vs. HFrEF (9,10). HFpEF patients 
are older and more likely female (11). Renal failure seems 
equally common in all HF patients, however, other so-called 
“non-cardiac” co-morbidities such as chronic obstructive 
pulmonary disease (COPD), diabetes, obesity and arterial 
hypertension are more prevalent in HFpEF (10,11).
The cardiac phenotype of HFpEF is characterized by 
increased LV filling pressure, a reduced LV stroke volume 
(SV) (at rest or during exercise) and blunted chronotropic 
response in some patients. Cardiac output (CO) greatly 
depends on myocardial pump function as well as the elastic 
properties of the subsequent arterial vasculature and venous 
blood flow returning to the heart. Their contribution may 
be of particular importance for right heart function in HF as 
discussed below (see “RVD in HFpEF”). Ventricular aortic 
coupling is reviewed in detail by Bernardo et al. in this issue 
of the Journal. Here, we will focus on molecular and cellular 
mechanisms of HFpEF at the level of the myocardium.
In the canonical view of HF(rEF) pathophysiology, 
neurohumoral activation and maladaptive cardiac 
remodeling are triggered by a reduction in myocardial 
contractile force that results from the replacement of 
functional cardiomyocytes by fibrotic scar tissue [e.g., 
following necrosis, apoptosis or both (12-15)]. While 
fibrosis is also a hallmark of remodeling in HFpEF 
(see “fibrosis/extracellular matrix” section), excessive 
cardiomyocyte death is not typical (16), even though 
an increased rate of apoptosis is observed in specific 
cardiomyopathies (17,18). Disease progression in HF is 
paralleled by an increased mechanical load on the cardiac 
myocytes, either by increased preload despite reduced 
SV or by increased afterload with the progression of co-
morbidities. Cardiac remodeling in HF is almost invariably 
associated with cardiomyocyte hypertrophy, which may 
be even more pronounced in HFpEF vs. HFrEF (19). In 
HFpEF, cardiomyocytes contribute to diastolic dysfunction 
by increased passive stiffness (see “the role of titin in 
impaired cardiomyocyte relaxation” and “inflammatory-
driven pathogenic pathways in HFpEF” sections). However, 
recent evidence indicates that systemic inflammation and 
metabolic dysregulation also impair excitation-contraction 
coupling (ECC) and thus active cardiomyocyte relaxation 
as discussed in “active cardiomyocyte relaxation” section. 
Hypertrophic cardiomyopathy (HCM), a genetic disorder 
of the myofilaments, is often associated with diastolic 
dysfunction, and—even in the absence of outflow tract 
obstruction—may lead to HFpEF (20). While implications 
of alterations in myofilament properties are discussed in 
“myofilament properties” section, we refer to more detailed 
recent reviews on the pathophysiology and presentation of 
HCM (20-22).
Increased myocardial passive stiffness
Increased myocardial passive stiffness is a hallmark 
feature of HFpEF. Two major components are relevant 
for increased passive stiffness: altered extracellular matrix 
composition and impaired cardiomyocyte relaxation.
Fibrosis/extracellular matrix
As extensively reviewed before (13,23-25), the amount of 
collagen, the abundance of collagen type 1 and collagen 
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cross-linking contribute to increased myocardial stiffness 
and diastolic dysfunction. In MRI studies, impaired diastolic 
function correlated with myocardial fibrosis (26), which 
is predominantly localized perivascularly and diffusely in 
the interstitial space (26,27) and is considered a hallmark 
feature of HFpEF (28). Fibrosis has also been related 
to inflammatory triggers (29). Consistently, myocardial 
inflammation has also been linked to increased collagen 
type 1 and enhanced collagen cross-linking in biopsies 
from HFpEF patients (30). Extracellular matrix is also 
influenced by other proteins that accumulate in the setting 
of comorbidities frequently associated with HFpEF. For 
instance, advanced glycosylation end-products (AGEs) 
are found in particular in patients with diabetes (31) and 
have been associated with myocardial inflam¬mation and 
HFpEF (32), although their role for impaired relaxation is 
debated (31). Interestingly, extracellular matrix stiffness has 
been shown to directly affect cardiomyocyte function and 
Ca2+ transients (CaTs) in a HFpEF model (33).
The role of titin in impaired cardiomyocyte relaxation
Titin exists in two main isoforms that contribute to 
myocardial stiffness, the N2B and the N2Ba isoform 
springs. As these isoforms show different compliances titin-
isoform switch, i.e., an altered N2B/N2BA ratio, is a well 
understood mechanism contributing to increased diastolic 
stiffness in a variety of cardiomyopathies (34). It is thus not 
surprising that isoform switch was identified as a main driver 
of HFpEF development (7). In addition, titin compliance 
is influenced by its phosphorylation state, tightly related 
to local inflammation and oxidative stress (35). It has been 
suggested that titin and cardiomyocyte related alterations 
are more important during early as compared to late 
stages of HFpEF (36). Interestingly, arterial hypertension 
with LV hypertrophy but without HF was not associated 
with alterations in titin or myocardial stiffness (24). 
The pathophysiology of titin has been extensively reviewed 
elsewhere (36-38). We address titin-based therapeutic 
approaches in “cGMP—signaling” section.
Active cardiomyocyte relaxation
Whereas passive mechanical properties of cardiomyocytes 
are evaluated in skinned myofibers obtained from animals 
and from human myocardial biopsies (“the role of titin in 
impaired cardiomyocyte relaxation” section), examination 
of active contraction and relaxation during ECC requires 
access to intact and functional myocardium and isolated 
cardiomyocytes (quantitative measurements of Ca2+ and 
Na+). Due to limited access to such samples from HFpEF 
patients, current data on ECC is mainly based on animal 
models. Advantages and limitations of currently available 
models have been comprehensively discussed recently (39).
Altered cytosolic Ca2+- and Na+-signaling
Cardiomyocyte contraction and relaxation is governed by 
the shape of the cytosolic CaT activating the myofilaments. 
Ca2+ release into the cytosol from the sarcoplasmic reticulum 
(SR) through ryanodine receptors (RyR2) is triggered by 
Ca2+ influx through L-type Ca2+ channels (LTCC) during 
the action potential (Ca2+-induced Ca2+ release) and is 
highly controlled within intracellular microdomains (dyads). 
Cytosolic Ca2+ removal is achieved mainly by the ATP-
dependent SR Ca2+ pump (SERCA) and to a lesser extent 
by extrusion via the sarcolemmal Na+/Ca2+ exchanger 
(NCX) balancing the influx of Ca2+ via LTCC during the 
cardiac cycle. Cardiomyocytes from end-stage HFrEF are 
characterized by increased diastolic [Ca2+]i, reduced peak 
[Ca2+]i, a slower cytosolic Ca
2+ removal and reuptake into 
the SR and a lower SR [Ca2+]. Most consistently related is 
a reduced activity of SERCA and increased SR Ca2+ leak 
through RyR2. In recent years, with the development of 
animal models more closely mimicking the co-incidence of 
relevant triggering co-morbidities in vivo, distinct and more 
diverse cardiomyocyte phenotypes have been described in 
HFpEF. As summarized in Table 1 alterations in cytosolic 
[Ca2+] have been observed in a variety of models in isolated 
cardiomyocytes ex vivo, indicating an adaptation of 
cardiomyocyte ECC in HFpEF even in the absence of the 
systemic metabolic and hemodynamic challenges present 
in vivo. Levels of diastolic [Ca2+] are often increased which 
not only reflects impaired relaxation but also influences 
the effects of Ca2+ release following depolarization (50). 
Cytosolic [Ca2+] decay is often prolonged, suggesting a 
contribution of prolonged active relaxation to diastolic 
dysfunction. In support, a close correlation between 
the [Ca2+] decay constant in isolated cardiomyocytes 
and the isovolumetric relaxation time in vivo has been 
documented in a cardiorenal HFpEF model (47). SR Ca2+ 
leak may be a sign of advanced stages of HFpEF (47). 
In contrast to end-stage HFrEF, the CaT amplitude {or 
SR [Ca2+], where determined} is not generally reduced 
and maybe even increased thus resembling the findings 
in “compensated” LV hypertrophy (51). Indeed, in a 
novel hypertrophic heart rat model without hypertension, 
diastolic dysfunction and congestion were associated 
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Rat: NXT x x x ↔ ↔ ↓ ↓ ↑ (39,40)
Rat: ZSF1 x x x x x ↑ ↔ ↓ (41)
Rat: SHR x x ↑ ↔ ↓ ↔ ↔ (42)
Rat: AB x x ↑ ↑ ↓ ↑ ↑ (43)
Rat: AB x ↔ ↓ ↔ ↓ ↓ ↓ ↓ (44)
Rat: ZDF x x x x ↔ ↑ ↔ ↔ (45)
Rat: NXT + 
DOCA
x x x ↔ ↔ ↔ (46)
Rat: HHR x x ↑ ↑ ↓ (47)
Pig: AB x x ↔ ↓ ↓ (48)
Human: 
CAB
x x ↔ ↑ (49)
x, clinical condition; ↔, unchanged vs. control; ↑, increased vs. control; ↓, decreased vs. control. HFpEF, heart failure with preserved ejection  
fraction; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; LVEDP, left ventricular end-diastolic pressure; CaT, Ca2+ 
transient; SR, sarcoplasmic reticulum; NXT, subtotal nephrectomy; ZDF, Zucker diabetic fatty rat; SHR, spontaneously hypertensive rat; 
ZSF1, ZDF crossed with SHR; AB, aortic banding; HHR, hypertrophic heart rat; DOCA, chronic deoxycorticosterone acetate treatment; 
CAB, coronary artery bypass with HFpEF.
with increased LTCC influx and CaT amplitudes which 
may indicate a compensatory increase in inotropy in 
response to fibrotic hypertrophic remodeling (40). 
On the other hand, modeling of human myocardium 
suggests that a concentrically hypertrophied ventricular 
wall can maintain a preserved EF even despite reduced 
sarcomere shortening at the cardiomyocyte level (41) as 
implicated by reduced CaT amplitudes observed in some 
studies (Table 1).
It must be noted that only a minority of studies evaluated 
the functional response of cardiomyocytes from HFpEF 
models on physiological stressors (e.g., pacing frequency, 
adrenergic stimulation). Thus, more data is needed 
to elucidate the heterogeneity of the cardiomyocytes’ 
functional response to exercise-related stimuli in HFpEF.
As opposed to end-stage HFrEF, a uniform pattern 
of expression of Ca2+ handling proteins has not emerged 
in HFpEF, but different modalities of post-translational 
regulation (e.g., oxidation, glycation, S-nitrosylation, 
phosphorylation) may contribute to altered Ca2+ trafficking, 
probably depending on HFpEF etiology (42,43). Also, 
increased cytosolic Ca2+ buffering slows Ca2+ trafficking 
and may decelerate Ca2+ decay and increase diastolic Ca2+ 
especially at higher heart rates (44,50).
Intracellular [Ca2+] is closely linked to [Na+] via the NCX 
which contributes to cytosolic Ca2+ removal even more in 
larger species and humans as compared to rodents (45). 
Increased [Na+] near the NCX can strongly influence the 
balance of transsarcolemmal Ca2+ fluxes and may thus 
contribute to altered cardiomyocyte relaxation in HFrEF 
(46,48). Potential mechanisms leading to intracellular Na+ 
accumulation in cardiomyocytes include late Na+ influx via 
fast (Nav1.5) Na+ channels (INa,late), increased activity 
of the Na+/H+ exchanger (NHE1), reduced activity of 
the ATP-driven Na+/K+-pump (NKA), and influx via the 
sodium glucose co-transporter (SGLT1), the Na+/K+/
Cl− co-transporter (NKCC1) or via less selective cation 
channels (e.g., TRP-channels). NCX undergoes complex 
mode shifts (forward/reverse) during the same cardiac 
cycle and may itself be a relevant source of Na+ influx into 
cardiomyocytes (49). However, the role of [Na+]i as a 
driver for diastolic dysfunction and the relevance of any 
of the mentioned mechanisms of Na+ accumulation in 
cardiomyocytes in HFpEF is still under debate (47,52,53). 
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While experimental data, also in human myocardium, 
support the concept to treat diastolic dysfunction by 
inhibition of INa,late in a variety of cardiac disease models 
(54-57), the INa,late inhibitor ranolazine failed to improve 
diastolic function acutely and after 14d in a small cohort of 
patients with HFpEF in a clinical phase IIa proof-of-concept 
study (RALI-DHF) (58). In a more recent study, muscle 
strips from the LV anterior wall (epicardial biopsies) of 
patients with hypertensive heart disease and HFpEF showed 
a prolonged relaxation time and a rate-induced increase 
in diastolic [Ca2+]. However, no frequency-dependent 
increase in cytosolic [Na+] or altered expression of Na+-/
Ca2+ handling proteins were detected, and neither the acute 
application of ranolazine, amiloride (inhibiting NHE1), or 
furosemide (targeting NKCC1) improved cardiomyocyte 
relaxation (59). These results have been interpreted to argue 
against a role of increased cardiomyocyte [Na+]i in HFpEF 
(16,59). However, the complex regulation of sarcolemmal 
[Na+] fluxes may not be reflected in the bulk cytosol (60,61), 
and the contrasting findings in different models warrant 
a more quantitative assessment of intracellular [Na+] 
dynamics and the evaluation of long-term adaptation of 
the cardiomyocyte to [Na+] influx modulation in different 
etiologies of HFpEF.
Myofilament properties
HCM is often associated with global hypercontractility but 
also diastolic dysfunction as characterized e.g., by increased 
LV end-diastolic pressure or LA remodeling, which may 
result in overt HFpEF (20). Depending on the underlying 
gene mutation, different micro- and macroscopic 
myocardial HCM phenotypes have been characterized (21). 
While myocardial passive stiffness is increased (by 
interstitial fibrosis and increased wall thickness), these 
effects are likely sequelae of dysfunctional sarcomeres. At 
the myofilaments, specific mutations have been associated 
with myofilament disarray with impaired Ca2+ cycling, an 
increased energy cost of contraction and/or pathologically 
increased myosin-actin binding during relaxation and 
even in the resting state (21). Based on the latter, a novel 
therapeutic approach currently in clinical trials investigates 
the effects of a first-of-its class myosin-ATPase inhibitor, 
mavacamten, in patients with symptomatic HCM or 
hypertrophic obstructive cardiomyopathy (HOCM) (62-64). 
First results of recent clinical phase 2 studies suggest 
good tolerability and improvement in some parameters of 
diastolic dysfunction (62,64).
While myofilament properties have been extensively 
studied in hypertrophic and dilated cardiomyopathy (65), 
the contribution of altered Ca2+ sensitivity and cross-bridge 
cycling to contractile dysfunction in other, more common 
etiologies of HFpEF is less well understood. Binding 
of Ca2+ to the troponin complex of the thin filament 
depends on the dissociation constant of troponin C (TnC). 
Adrenergic, PKA-dependent phosphorylation of troponin 
I (TnI, at Ser23/24) and cardiac myosin-binding protein C 
(cMBP-C) can reduce myofilament Ca2+ sensitivity by an 
altered TnC-TnI interaction and thus enhance relaxation 
of the myofilaments (66,67). Myosin-ATPase forms the 
motor of cross-bridge cycling by converting energy into 
myofilament motion. In HFrEF, an activator of myosin-
ATPase is currently evaluated in clinical trials to improve 
CO without changing the kinetics of contraction (68), 
whereas inhibition of a hypercontractile myosin-ATPase 
in genetic cardiomyopathies has been shown to prevent 
hypertrophic remodeling (69). The role of myosin-ATPase 
in HFpEF has not yet been explored.
In one of the few studies on active myofilament function 
in HFpEF, the expression of the sarcomeric proteins 
cMyBP-C, cTnI, and cardiac myosin light chain 2 (cMLC2) 
were found unaltered in old dogs with hypertension-
induced LV hypertrophy and diastolic dysfunction (70). 
However, phosphorylation of cMyBP-C (–80% at S282), 
TnT, TnI, and MLC2 (–70% at S19) was reduced resulting 
in increased Ca2+ sensitivity, reduced maximal activated 
tension, and slowed relaxation. Interestingly, PKA activity 
was not different but expression of phosphatases (PP1 and 
PP2a) was increased. Reduced cMYBP-C phosphorylation 
has been directly linked to diastolic dysfunction (71) and 
its dysregulation may contribute to HFpEF in the aging 
heart (72).
Lovelock et al. also reported increased myofilament 
sensi t izat ion (DOCA HFpEF rat) .  In this  s tudy, 
glutathionylation rather than phosphorylation of MyBP-C 
was associated with cardiomyocyte dysfunction (73). 
Analogously a variety of different post-translational 
modifications at the level of the myofilament proteins have 
been associated with diastolic dysfunction, including among 
others glutathionylation, methylglyoxal modification or 
oxidation, highlighting the variability and complexity of 
upstream signaling pathways (74-76).
Metabolic dysregulation
Metabolic dysregulation—i.e., the clinical alterations of 
diabetes mellitus, hypercholesterinemia and adiposity—is 
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closely linked to HFpEF and within this population conveys 
an even worse prognosis (7,11,77). Adiposity, in particular, 
is an independent risk factor for the manifestation and 
progression of HFpEF (78,79). A considerable number 
of patients with HFpEF [24–45% (11)] suffer from type 
2 diabetes mellitus promoting inflammation, increased 
interstitial fibrosis and collagen stiffening (39). At the 
cellular level, several aspects of metabolic dysregulation 
may contribute to HF (80), including an increased supply 
of the heart with energy substrates [“fuel overload” (81)], 
accumulation and dysfunctional processing of energy 
substrates within the myocardium (82,83) (Figure 1), and 
metabolic imbalance in peripheral tissue due to reduced 
CO and consequential reduced oxygen utilization in the 
peripheral tissue (84,85).
In healthy cardiomyocytes, the vast majority of ATP 
(>90%) is generated in the mitochondria by oxidative 
phosphorylation of fatty acids (FAs, 60%) or glucose 
(40%) (82). Increased glycolysis in combination with 
unchanged glucose oxidation (i.e., glycolytic uncoupling) 
was observed early in DOCA HFpEF rats (86). Collectively, 
the majority of current clinical and experimental studies 
in diabetic/obese as well as non-diabetics suggest that 
development of HFpEF (as opposed to HFrEF) is 
accompanied by increased FA oxidation and reduced glucose 
oxidation [see (83) for a comprehensive review]. Increased 
FA uptake is also observed in RV dysfunction [see Agarwal 
et al. in this issue (doi: 10.21037/cdt-20-404)]. Glucose 
oxidation is more effective, i.e., it yields more high-energy 
phosphate bonds per mol O2 than FA, whereas FA yield 
Figure 1 Mechanisms of cardiomyocyte dysfunction in HFpEF. Cardiomyocyte phenotypes include altered ion homeostasis (increased 
cytosolic Ca2+ and Na+ load), increased myofilament Ca2+ sensitivity, slower sarcomere relaxation and increased passive stiffness linked to 
reduced cGMP-PKG-mediated signaling. Mitochondrial oxidative capacity is reduced due to dysregulated intracellular metabolic processing 
despite an increased external supply with energy substrates. ROS (from mitochondria and external sources) and reduced NO availability 
contribute to increased oxidative and nitrosative stress and metabolic toxicity. HFpEF, heart failure with preserved ejection fraction; ROS, 
reactive oxygen species; NO, nitric oxide.
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more energy per gram substrate than glucose if oxidation is 
not limiting (87). Comparison of ZSF-1 (diabetic obese) and 
DOCA + high salt diet (hypertensive) rat HFpEF models 
suggests differential regulation of oxidative phosphorylation 
depending on the HFpEF trigger (88). Also, in a porcine 
model of HFpEF induced by aortic banding, magnetic 
resonance spectroscopy imaging indicated a switch from FA 
towards glucose substrate utilization in the myocardium (89), 
again highlighting the complexity of HFpEF(-like) 
phenotypes. As a result of metabolic dysregulation, data 
from animal experiments suggest a decrease in cardiac (and 
peripheral) mitochondrial ATP production in hypertrophic 
hearts with diastolic dysfunction (90). In addition, structural 
changes associated with a reduced availability of functional 
mitochondria have been described in HFpEF (91).
In patients with HFpEF the ratio between cardiac 
creatine phosphate and adenosine triphosphate is reduced 
suggesting a reduced energy reserve (92).
In HFrEF mitochondrial remodeling has been linked to 
an increased mitochondrial production of reactive oxygen 
species (ROS). It is currently unclear whether mitochondrial 
ROS production in cardiomyocytes is increased in HFpEF. 
Another source for ROS is uncoupling of nitric oxide 
synthase (NOS) by a HFpEF-related reduction of the co-
enzyme biopterin (93). Increased ROS add to oxidative/
nitrosative stress and may interfere with a variety of 
intracellular signaling pathways (e.g., via CaMKII) by post-
translational protein modification (Figure 1). ROS formation 
may be less evident in early HFpEF (94). In light of these 
findings, therapeutic approaches targeting mitochondria (i.e., 
to stimulate mitochondrial ATP production or reduce ROS) 
are currently evaluated (85). It has been proposed but not yet 
clinically validated that NO-cGMP related signaling may also 
increase the quantity of functionally active mitochondria thus 
potentially improving myocardial oxygen consumption (95). 
Interestingly, mitochondrial dysfunction has also been 
demonstrated in models of RV failure as reviewed by 
Agarwal et al. in this issue (doi: 10.21037/cdt-20-404).
Mitochondrial Ca signaling
In cardiomyocytes ATP consumption (mainly by the 
myofilaments) is tightly coupled to ATP production in 
the mitochondria via Ca2+ fluxes from the cytosol to the 
mitochondria (96). While disruption of the tight coupling 
between the cytosolic Ca2+ release units may contribute 
to impaired myofilament energy supply in HF, high 
mitochondrial Ca2+ exposure (as in myocardial ischemia 
with cytosolic Ca2+ overload) induces cardiomyocyte 
apoptosis (97). In pressure overload-induced LV remodeling 
this delicate balance may be decisive for the transition 
from compensated hypertrophy to HF (98). Mitochondrial 
signaling in HFpEF is not yet well understood. In a porcine 
aortic banding model, mitochondria from HFpEF hearts 
were more susceptible to Ca2+ overload (99). In addition, a 
recent study showed that increased cytosolic Ca2+ turnover 
in HFpEF (see “altered cytosolic Ca2+- and Na+-signaling” 
section) was associated with increased mitochondrial Ca2+ 
load leading to reduced oxidative capacity and mitochondrial 
swelling. Based on these early data, protecting mitochondria 
from the cytosolic Ca2+ challenge should be evaluated as a 
therapeutic approach in HFpEF.
HFpEF—alterations in signaling
Systemic inflammation
I n f l a m m a t i o n  h a s  b e e n  e p i d e m i o l o g i c a l l y  a n d 
mechanistically linked to HFpEF (100). Broadly identified 
as a non-specific defensive response of the organism to 
threats, inflammatory pathways are active in HFpEF and, 
importantly, contribute to its pathogenesis.
HFpEF is a syndrome driven by multiple comorbidities 
and conditions (27). Virtually, all of these (e.g., obesity, 
hypertension, aging etc.) are characterized by a status of 
subtle, chronic systemic inflammation contributing to 
the overall complex inflammatory activation in HFpEF. 
Although both the clinical significance and specific 
pathways of inflammatory alterations in HFpEF are yet to 
be fully determined, accumulating clinical and experimental 
evidence suggest that immune dysregulation is critical in 
the pathophysiology of HFpEF.
Clinical evidence of HFpEF as inflammatory disease
Some of the most striking evidence supporting a role 
for inflammation as key element of HFpEF progression 
are based on circulating biomarker discovery. Classical 
biomarkers of myocyte stretch and necrosis (NP and 
troponins) have less diagnostic value in HFpEF, compared 
to HFrEF (101). On the other hand, increased circulating 
levels of canonical inflammatory cytokines [e.g., tumor 
necrosis factor-alpha, soluble tumor necrosis factor-receptor 
I (sTNFRI), interleukin (IL)-6 and IL-1] were found to be 
predictive of incident HFpEF but not HFrEF (102-104). 
More recently, a European network analysis of circulating 
biomarkers in HF subjects revealed a unique biomarker 
preponderance related to inflammatory response, leukocyte 
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migration and cell adhesion in HFpEF patients (105).
Multiple phenotypes of HFpEF can be identified 
and categorized in different phenogroups that only 
partially overlap in terms of prevalence of comorbidities, 
pathophysiological mechanisms and clinical outcomes. The 
use of machine learning techniques has recently allowed the 
identification of distinctive biomarker profiles in different 
HFpEF phenogroups (102,106). Of interest, the presence 
of metabolic alterations seems to identify the phenogroup(s) 
with the greatest inflammatory activation. Specifically, 
increased adiposity has been associated with clusters of 
biomarkers related to immune activation and inflammation 
in specific HFpEF subgroups. The increase in circulating 
biomarkers of inflammation in HFpEF is supportive of 
the multiorgan, systemic inflammatory involvement in 
this syndrome. In addition, inflammatory activation (i.e., 
infiltrating immune cells and increased levels of critical 
mediators of inflammation) was demonstrated in HFpEF 
endomyocardial biopsies (30,107).
Based on these findings, inhibition of inflammation 
has been explored as therapeutic strategy in HFpEF. 
For example, blockade of IL-1 signaling in HFpEF with 
anakinra has been tested in the D-HART and D-HART2 
clinical studies. While in the pilot D-HART study, HFpEF 
patients treated with anakinra showed improved aerobic 
exercise capacity (108), these findings were not confirmed 
in the subsequent phase II study (109). Failure of this anti-
cytokine therapeutic approach might be attributable to 
the heterogeneity of unselected HFpEF population. The 
accurate phenotypic sub-classification of HFpEF patients 
together with the characterization of specific inflammatory 
pathways active in different HFpEF subgroups will 
be critical to identify clusters of HFpEF patients that 
may benefit most from anti-inflammatory therapeutic 
approaches.
Inflammatory-driven pathogenic pathways in HFpEF
The clinical evidence for HFpEF as an inflammatory 
disease is corroborated by preclinical studies focusing on the 
mechanistic aspects of this syndrome. Notably, the current 
knowledge is limited to inflammatory mediators and aspects 
of innate immunity, whereas the involvement and extent of 
alterations of adaptive immunity in HFpEF is still largely 
unknown (110).
In HFpEF, inflammation has been implicated in 
promoting coronary microvascular endothelial dysfunction 
and in the perturbation of NO availability, two hallmarks 
of myocardial alterations in HFpEF. Increased expression 
of  adhes ion molecules  in  the inf lamed coronary 
endothelium drives the recruitment and infiltration of 
macrophages and other inflammatory cells promoting 
the development of interstitial fibrosis, which together 
with cardiomyocyte stiffening, contributes to diastolic 
dysfunction in HFpEF (111). For example, hypertension-
induced diastolic dysfunction in mice causes the expansion 
of cardiac macrophage pools associated with the increased 
production of pro-fibrotic IL-10 which, in turn, amplifies 
and perpetuates diastolic dysfunction (112). Yet, the precise 
molecular events triggering the contribution of immune 
cells to diastolic dysfunction in HFpEF are still unknown.
Comorbidit ies-driven inf lammation in HFpEF 
severely impacts on NO bioavailability in this syndrome. 
Inflammation increases oxidative stress and the production 
of ROS in HFpEF hearts, converting, in part, NO into 
peroxynitrite and other NO-related reactive species. In 
line with this notion, the presence of nitrosative stress 
in HFpEF has been identified as a major driver of this 
syndrome (113) (Figure 1).
The inflammatory-dependent reduction of NO 
bioavailability lowers the intracellular levels of cGMP, 
resulting in cardiomyocyte stiffening and impaired cellular 
relaxation (see “the role of titin in impaired cardiomyocyte 
relaxation” and “cGMP—signaling” sections).
Dysregulated NO production in HFpEF also involves 
the upregulation of inducible NOS (iNOS), a major 
inflammatory mediator, as shown in the myocardium of 
clinically relevant model(s) of HFpEF as well as in HFpEF 
human endomyocardial biopsies (72,107). The resulting 
nitrosative stress impacts on cardiomyocyte function at many 
levels perturbing fundamental signaling pathways involved 
in cardiomyocyte responses to chronic stress (Figure 1). 
Interestingly, the role of iNOS in promoting cardiomyocyte 
dysfunction has been associated with metabolic syndrome 
and hypertension, comorbidities present in the majority of 
HFpEF patients. This suggests iNOS as a crucial effector 
of metabolic stress-induced inflammation—i.e., metabolic 
inflammation or metainflammation—and thus, as a common 
mechanism between HFpEF and other metabolic diseases 
that might present a valuable therapeutic target across many 
inflammatory-driven disorders.
Neurohumoral activation
A recent clinical study suggests that neurohumoral 
activation—as quantified by elevated plasma renin activity, 
aldosterone or catecholamine levels—is less prevalent 
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in HFpEF vs. HFrEF (114). Similarly, HFpEF was not 
associated with significant RAS activation as measured by 
ACE activity (94). These observations agree with earlier 
results indicating that neurohumoral activation (RAS and 
sympathetic) in HF is related to the degree of reduction in 
LV EF (115,116). Along similar lines, plasma aldosterone 
levels correlate with LV hypertrophy but not (independently) 
with LV diastolic dysfunction in patients with arterial 
hypertension (117). These findings may in part explain 
why RAS antagonists have failed to achieve survival benefit 
in HFpEF clinical trials (4,118). Interestingly, despite 
effectively reducing arterial blood pressure, RAS-inhibition 
is also not associated with improved LV remodeling in 
patients with preserved EF (119). Taken together, current 
evidence suggests that RAS activation may be present in 
some HFpEF patients but is likely not a relevant driver for 
diastolic dysfunction or increased morbidity and mortality 
(Figure 2). The role of aldosterone antagonists in HFpEF, 
however, remains to be determined (120).
In line with above findings on neurohumoral activation, 
betablockers have not been found beneficial in clinical 
studies in HFpEF patients, and maybe even harmful by 
worsening impaired chronotropic responses in some 
patients (121). In fact, withdrawal of pre-existing 
betablocker therapy in HFpEF patients is currently 
investigated as a therapeutic approach (122).
cGMP—signaling
In HFpEF, increased myocardial passive stiffness, in large 
parts mediated by the sarcomeric protein titin, has been 
associated with reduced activity of the cGMP-protein kinase 
G-signaling cascade in cardiomyocytes. Physiologically 
NO (from intra- and extracellular sources, Figure 1) and 
NP stimulate guanylyl cyclases (GCs) to maintain cGMP 
homeostasis. Increased levels of NP are considered a 
protective response in HF (123). In HFpEF, however, 
reduced bioavailability of NO, reduced efficacy of NP, and 
direct impairment of GC function (by oxidative stress) 
synergize to cause an intracellular lack of cGMP. Based on 
encouraging experimental data, several pharmacological 
approaches to increase cGMP were evaluated in clinical trials: 
soluble GC stimulators/activators, NO donors, inhibitors 
of the degradation of either cGMP (PDE5-inhibitors) or 
BNP (sacubitril/valsartan). To date, none of these clinical 
approaches has resulted in prognostic benefits in HFpEF 
patients, but stimulation of the cGMP-PKG-dependent 
pathway remains an attractive strategy as discussed in (124).
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Right ventricular dysfunction (RVD) in HFpEF
Clinical prevalence and prognostic value
RVD, often in conjunction with pulmonary hypertension 
(PH), is commonly observed in patients suffering from 
HFpEF and closely related to worse clinical outcomes 
evident as increased hospitalization rates and a considerable 
increase in overall mortality as compared to HFpEF 
patients without RVD (125-127) (for an in depth review 
on RVD mortality see also Sanders et al. in this issue, doi: 
10.21037/cdt-20-450). Therefore, detailed and longitudinal 
RV phenotyping of HFpEF patients is warranted to identify 
individuals at higher risk for adverse cardiac events or on a 
declining trajectory.
In the past, only a few studies have systematically 
screened for RVD in patients with HFpEF with considerable 
variation in reported prevalence between and even within 
studies. Puwanant and colleagues detected impaired RV 
function, defined as a decline in echocardiographically-
assessed RV fractional area change (FAC) below 45%, in 
approximately 33% of a total of 51 HFpEF patients (128). 
Yet, when the authors defined RVD as tricuspid annular 
plane systolic excursion (TAPSE) of <15 mm or peak 
systolic tricuspid annular tissue velocity S’ <115 mm/s, 
which both assess RV systolic performance, 40% and 
50% of HFpEF patients, respectively, were classified 
with RVD (128). A larger study of 309 HFpEF patients, 
however, reported RVD in only 20% of HFpEF patients, 
albeit using a slightly higher TAPSE of <15.9 mm as 
cut-off (129). In yet another cohort of 201 HFpEF patients, 
speckle-tracking echocardiography-derived RV strain 
identified RV systolic and diastolic abnormalities in 75% and 
48% of patients, respectively (130). Finally, in a community-
based study from Olmsted County, Minnesota, of 500 
patients identified with HFpEF 35% and 21% showed signs 
of RVD as defined by a TAPSE of <16.0 mm or by semi-
quantitative two-dimensional echocardiography (i.e., visual 
assessment of RV contractility, and comparison of RV to LV 
size, summarized on a four-point ordinal scale) (131).
The considerable variability between studies in the 
reported prevalence can be in part attributed to differences 
in study populations (age, sex, comorbidities, medications), 
deviating study protocols for clinical assessment of RVD, 
and use of different cut-off values (132). While these 
variabilities preclude a precise estimate of the prevalence 
of RVD in HFpEF patients, one can conclude that RVD 
is a common comorbidity in HFpEF, with an average 
prevalence of 30% based on TAPSE criteria. As such, RVD 
should deserve special attention in HF phenotyping (133).
Importantly, in all of the above studies RVD was 
diagnosed based on echocardiographic assessment of 
RV morphology and function, rather than invasive 
measurements of systolic, mean, and diastolic pulmonary 
artery pressure (PAP) as well as pulmonary capillary wedge 
pressure (PCWP) as a direct reflection of increased RV 
afterload, to which the RV is particularly vulnerable. 
Although the etiology of increased RV afterload in HFpEF 
initially is primarily attributable to increased left-atrial (LA) 
filling pressures and subsequent retrograde congestion of 
the pulmonary veins, capillaries and arteries, the resulting 
PH is frequently complicated by secondary pulmonary 
vascular remodeling (134) (for discussion of the underlying 
mechanisms please see below). As such, assessment of 
the transpulmonary pressure gradient (TPG; mean PAP-
PCWP) or diastolic pressure gradient (DPG; diastolic PAP-
PCWP) constitutes an important diagnostic test for left 
and right heart disease (135). Accordingly, state-of-the-art 
diagnostic HFpEF guidelines recommend the assessment 
of PCWP for a subgroup of patients as part of a diastolic 
stress testing (136). Given the risks associated with right 
heart catheterization, invasive hemodynamic phenotyping 
of the right heart is, however, scarcely performed. Indeed, 
simultaneous left and right heart hemodynamics may be 
warranted in some patients as outlined by Hansmann et al. 
in this issue (doi: 10.21037/cdt-20-483).
The prognostic relevance of RVD in HFpEF patients 
was highlighted by the group of Margaret Redfield in 
the already mentioned Olmsted County study (131) 
demonstrating that all-cause and cardiovascular mortality, 
as well as time to first or multiple HF hospitalizations are 
associated with increased systolic PAP, decreased TAPSE, 
and semi-quantitative confirmation of RVD. These findings 
were corroborated in a subsequent study which reported an 
almost 10-fold higher 1-year all-cause mortality for HFpEF 
patients with RVD compared to those without (41.7% vs. 
4.8%) (127). On the basis of these data, it seems compelling 
that HF phenotyping guidelines need to implement 
standardized RV phenotyping protocols to identify patient 
populations who evidently face the greatest risk for critical 
events.
Potential mechanisms of RV dysfunction
HFpEF causes “passive” backward congestion of blood 
pressure from the left ventricle into the pulmonary 
circulation and ultimately, the RV; however, with 
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advancing HFpEF severity and duration additional “active” 
mechanisms such as lung vascular remodeling and LV-RV 
interaction come progressively into play. While normal 
RV function is often maintained during mere passive 
congestion—frequently referred to as “isolated post-
capillary PH” (IpcPH)—additional “active” pulmonary 
vascular remodeling will result in “combined post- and 
pre-capillary PH” (CpcPH) which directly determines the 
extent and course of RVD (137,138).
Postcapillary pressure overload
The “passive” component of backwards congestion in left 
heart disease (LHD) is based on the basic physical principle 
of pressure transmission along communicating pipes that 
ultimately results in PH. While PH was originally, yet 
somewhat arbitrarily, defined as mean PAP ≥25 mmHg, 
a series of seminal studies published in the past 5 years 
revealed that individuals with a mean PAP of 21 to 24 mmHg 
are also at increased risk for poor outcomes (139,140). At 
the 6th World Symposium for Pulmonary Hypertension in 
Nice in 2018, these findings led to the recommendation to 
define a mean PAP ≥20 mmHg as new cutoff for diagnosing 
PH (141). Of the 5 different groups of PH, the most 
common one is PH-LHD which in addition to an increase 
in mean PAP ≥20 mmHg is defined by a concomitant 
PCWP >15 mmHg (142-144). Remarkably, epidemiological 
data suggest that PH-LHD (and thus, presumably, 
also RVD) is more frequent in HFpEF (83%) (145) 
as compared to HFrEF patients (68%) (146). This 
differential prevalence is in line with basic physiological 
principles (Figure 3): The hallmarks of HFpEF are 
concentric LV hypertrophy and diastolic dysfunction; in 
contrast, HFrEF is characterized by systolic dysfunction 
and LV dilatation. As a result, end-diastolic volumes (EDVs) 
are considerably smaller in HFpEF as compared to HFrEF, 
and even though LV EF will by definition be higher, the 
resulting LV SV will be smaller in HFpEF as compared to 
HFrEF (147). Importantly, it is the difference in SV, not in 
EF that characterizes ventricular output imbalance. Given 
the more pronounced reduction in LV SV, it may thus come 
as little surprise that PH-LHD is apparently more frequent 
in HFpEF as compared to HFrEF.
The current  nomenclature c lass i f ies  “pass ive” 
postcapillary pressure overload as IpcPH, defined as PH-
Figure 3 RVD in HFpEF vs. HFrEF. HFpEF is characterized by concentric LV hypertrophy. In turn, LV cavity size, EDV, and ultimately 
SV decrease. The resulting ventricular output imbalance between LV and RV increases the prevalence of PH-LHD and hence, the 
probability of RVD. Conversely, HFrEF causes LV dilatation, increasing LV cavity size and EDV. This enables the LV to transiently 
maintain a stable SV despite a reduced EF. As a consequence, ventricular output imbalance, PH-LHD and ultimately RVD are less common 
in HFrEF. RVD, right ventricular dysfunction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced 
ejection fraction; LV, left ventricular; EDV, end-diastolic volume; SV, stroke volume; PH-LHD, pulmonary hypertension associated with left 
heart disease.
HFrEF
Lv eccentric hypertrophy 
↑ LV cavity size 
↑ EDV 
Transiently maintained SV 
Balanced ventricular output 
PH-LHD (68%) 
Medium probability for RVD
LV concentric hypertrophy 
↓ LV cavity size 
↓ EDV 
↓ SV 
Ventricular output imbalance 
PH-LHD (83%) 
High probability for RVD
HFpEF
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LHD with a pulmonary vascular resistance (PVR) ≤3 Wood 
units, a DPG <7 mmHg, or a pulmonary artery compliance 
≥2.3 mL/mmHg (Table 2). Pathologically, IpcPH is 
primarily characterized by the typical signs of congestive 
HF, i.e., interstitial and subsequent alveolar lung oedema, 
which in case of capillary stress failure can advance to 
alveolar hemorrhage (148).
Precapillary PH
When “active” pulmonary vascular remodelling adds a 
precapillary component to the post-capillary pressure 
overload, IpcPH transitions to CpcPH defined as PH-
LHD with a PVR >3 Wood units, a DPG ≥7 mmHg, or a 
pulmonary artery compliance <2.3 mL/mmHg (Table 1). The 
underlying changes in the pulmonary vasculature comprise 
both medial and intimal thickening across the entirety of 
small vessels in the lung (134,149,150). The combined 
“passive” and “active” effects of HFpEF and pulmonary 
vascular remodeling ultimately affect the function of the 
RV (for a comprehensive overview on the non-invasive and 
invasive assessment of RV hemodynamics see Bernardo 
et al. and Truog et al. in this issue, doi: 10.21037/cdt-20-
479, doi: 10.21037/cdt-20-272). In response to the elevated 
afterload, the RV undergoes compensatory concentric 
hypertrophy and at its peak, is able to increase contractility 
by a factor of five (144). This phenomenon is commonly 
described as RV-PA coupling, which describes the energy 
transfer between RV contractility and arterial afterload, 
where RV contractility can be characterized by end-systolic 
elastance (Ees). Arterial afterload can be thought of as net 
arterial stiffness (Ea) (151,152). With disease progression, 
intraventricular pressure rises exerting increased stress on 
the RV wall inevitably leading to RV dilation. Increasing 
oxygen demand (required to pump against an increased 
afterload) can no longer be matched by a decreasing oxygen 
supply as diastolic coronary perfusion is progressively 
reduced as a result of increased ventricular wall tension. 
In combination, these events trigger a downward spiral of 
ischemia, deteriorating contractility, failing RV CO and 
ultimately general decompensation (142).
LV-RV interaction
An additional characteristic feature of RVD in HFpEF 
patients is tricuspid valve (TV) regurgitation due to 
enlargement of the TV annulus - preferably at the level 
of the free wall as a consequence of RV dilation (153). 
Similarly or in parallel, regurgitation may be caused by 
papillary muscle displacement as a result of RV remodeling 
(154). Finally, TV regurgitation may be directly driven by 
pathological changes in cardiac geometry: The transmission 
of LV structural and locomotorical changes via the 
interventricular septum to the RV increases the risk of 
TV leaflet prolapse and affects the position of the septal 
leaflet up to a point where efficient valve coaptation is no 
longer possible (155,156). The resulting TV regurgitation 
will further contribute to RV dilation and impaired RV 
CO, thus adding to the vicious cycle of accelerating RV 
failure. The latter scenario also underlines that in addition 
to “passive” congestion and “active” pulmonary vascular 
remodeling, direct interaction between the RV and LV 
may drive RVD in HFpEF. Conversely, the progressive 
increase in RV afterload in CpcPH may further negatively 
impact on LV diastolic function, as indicated by the 
clinical finding that release of RV afterload by pulmonary 
thrombarterectomy markedly improves LV EDV and 
SV (157). This RV-LV interaction is probably mediated 
in large part through septal interdependence, as leftward 
displacement of the interventricular septum further impedes 
LV filling (158). Notably, RV-LV interdependence extends 
beyond the level of hemodynamic interactions (158), but 
may comprise local remodeling and pro-fibrotic effects 
at the ventricular hinge-points (159) as well as vascular 
information transfer via gap junction-mediated conducted 
responses that can propagate to the contralateral ventricle 
along the continuity of the shared RV-LV microvasculature.
Future molecular approaches to HFpEF
As outlined in this review, current clinical and experimental 
evidence supports the concept of inflammation contributing 
to HFpEF pathogenesis. However, a better understanding 
Table 2 Hemodynamic definitions of PH
PH type Hemodynamic definitions
PH-LHD mPAP ≥20 mmHg; PCWP >15 mmHg
IpcPH PVR ≤3WU; DPG <7 mmHg; CPA ≥2.3 mL/mmHg
CpcPH PVR >3WU; DPG ≥7 mmHg; CPA <2.3 mL/mmHg
Modified from (138). PH-LHD, pulmonary hypertension  
associated with left heart disease; mPAP, mean pulmonary 
artery pressure; PCWP, pulmonary capillary wedge pressure; 
IpcPH, isolated post-capillary pulmonary hypertension; CpcPH, 
combined post- and precapillary pulmonary hypertension; PVR, 
pulmonary vascular resistance; WU, Wood units; DPG, diastolic 
pressure gradient; CPA, pulmonary artery compliance.
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of targetable signaling pathways is needed to translate these 
discoveries into novel therapeutic approaches. To this end, 
the careful phenotyping of clinically relevant animal models 
in vivo and in vitro, both at rest and during exercise/stress 
is mandatory in order to characterize a functional response 
rather than a steady state. While chronic inflammation sets 
the stage for cardiac remodeling, different co-morbidities 
likely trigger specific patterns of cellular adaptations which 
need to be delineated preferably in a structured comparison 
of animal models. Targeting well established pathways (e.g., 
cGMP-PKG) calls for novel approaches [such as inhibition 
of different PDEs (160) or sGLT inhibitors (161)]. Efforts 
to exploit identified mitochondrial-based therapeutic 
approaches (anti-ROS, pro ATP) are already underway (85). 
Cardiomyocyte ECC is tightly controlled and interventions 
targeting intracellular Na+ and Ca2+ need to take chronic 
adaptation of ion homeostasis into account (52). Myocardial 
fibrosis—while prevalent in HFpEF—requires validation 
as therapeutic target using established (spironolactone) and 
novel substances with anti-fibrotic activity (162). Promoting 
a targeted therapeutic approach (6), a more in-depth clinical 
phenotyping including comprehensive imaging analysis of 
both ventricles (strain, LA and RV involvement) and multi-
biomarker panels (163,164) will be the basis for HFpEF 
treatment with the goal to identify phenogroups of patients 
who may have the highest likelihood to benefit from a 
specific targeted therapy.
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